Date: 2017-01-10
Type of
information: Initiation of the trial
phase: 1b
Announcement: initiation of the trial
Company: Autifony Therapeutics (UK)
Product: AUT00206
Action
mechanism: Kv3 potassium channel modulator
Disease: schizophrenia
Therapeutic
area: CNS diseases - Mental diseases
Country: UK
Trial
details: (NCT02935725)
Latest
news:
- • On January 10, 2017, Autifony Therapeutics announced the initiation of a Phase Ib study to evaluate the effects of AUT00206 on Blood Oxygen Level Dependent (BOLD) signals during a ketamine challenge in healthy male subjects. The study, which is being carried out by Professor Bill Deakin at the University of Manchester, follows a preclinical ketamine challenge study that demonstrated significant effect of AUT00206. The clinical study will recruit 16 healthy volunteers in a four-way crossover design. The programme is supported by the Biomedical Catalyst, jointly funded by Innovate UK and the Medical Research Council, who also contributed important enabling funding towards the preclinical stages of the programme, in collaboration with the Universities of Manchester and Newcastle.
Is
general: Yes
